Palmetto GBA
Skip
permaLink
Ohio Part B Carrier
FDA Approval of Feraheme

On June 30, 2009, the FDA approved Feraheme, an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). Therefore, Palmetto GBA will reimburse Feraheme for patients diagnosed with chronic kidney disease.
 
To submit Feraheme services:
  • Submit HCPCS code J3490 – unclassified drugs
  • Enter the following information in the comment/narrative note field:
    • NDC number
    • Drug name
    • Dosage

 

last updated on 09/01/2009
CMS